Table 10.

Tabular summary

Etanercept
First approved in Germany	2002 (Psoriasis arthritis )/2004 (psoriasis vulgaris)
Recommended control parameters	Prior to therapy exclusion of tuberculosis, complete blood count, liver and renal values, urinanalysis
Recommended initial dosage	Twice 25 mg per week or 2× 50 mg/week
Recommended maintenance dosage	Twice 25 mg per week
Expected beginning of clinical effect	After 4–8 weeks, at the latest after 12 weeks
Response rate	PASI 75 in 34% (2 × 25 mg) or 49% (2 × 50 mg) of the patients at the end of the induction phase (12 weeks) (LE 1)
Important contraindications (limited selection)	Infections, pregnancy, nursing, heart failure NYHA III–IV
Important ADRs (limited selection)	Local reactions, infections
Important drug interactions (limited selection)	Anakinra (IL-1 receptor antagonist)
Other	–